Skip to main content

TARS Tarsus Pharmaceuticals, Inc.

Healthcare

70.50

Close 10/21

Open
70.85
High
72.81
Low
70.20
Prev close
71.03
Volume
945.9K
P/B
8.9
52W 53.89 91.53
Loading candles…

Is Tarsus Pharmaceuticals, Inc. a buy? Fundamentals and valuation first

As of 2026-10-21

Growth: Good, Momentum: Good, Risk / liquidity: Good; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E -64.68 N/A
Price / book 8.92 91th percentile Expensive
Free-cash-flow yield (%) 1.99 53th percentile Good
Quality Neutral FCF margin, TTM is Good, but Operating margin, TTM is Average.
ROE, TTM (%) -13.4 28th percentile Average
Operating margin, TTM (%) -8 26th percentile Average
FCF margin, TTM (%) 10.15 62th percentile Good
Growth Good Revenue growth, TTM YoY is Top, but Diluted EPS growth, TTM YoY is Average.
Revenue growth, TTM YoY (%) 105.17 92th percentile Top
Diluted EPS growth, TTM YoY (%) -53.22 34th percentile Average
Momentum Good 60-day return is Top; 240-day return is Good.
60-day return (%) 19.59 90th percentile Top
240-day return (%) 3.37 56th percentile Good
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 58,062,268 83th percentile Top
60-day annualized volatility (%) 48.03 53th percentile Average

Continue researching Tarsus Pharmaceuticals, Inc. with this page's evidence.

Continue in Studio ↗

Tarsus Pharmaceuticals, Inc. (TARS) peers and tracking

Watchlist

This page refreshes daily after the close. Add Tarsus Pharmaceuticals, Inc. to your watchlist to track signal changes on your next visit.

Tarsus Pharmaceuticals, Inc. (TARS) quant signal backtests

Market-wide momentum baseline

Across 98,747 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.49%, a 58.5% positive-return rate, and +3.13 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

More history: Signals not active now

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

9 times historically; 60-day forward avg +8.23%, win rate 50%, beating the market by +6.8 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

14 times historically; 60-day forward avg +1.2%, win rate 35.7%, beating the market by -2.31 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

5 times historically; 60-day forward avg +16.24%, win rate 80%, beating the market by +13.12 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

15 times historically; 60-day forward avg +10.56%, win rate 53.3%, beating the market by +5.79 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.